Advanced Lung Cancer
Conditions
Brief summary
To evaluate the efficacy and safety of TQB6411 for injection in trial participant with advanced lung cancer
Interventions
DRUGTQB6411 for Injection
TQB6411 for Injection is administered every 21 days as a treatment cycle. TQB6411 for injection is administered every 28 days as a treatment cycle.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance; * Age between 18 and 75 years (calculated based on the date of signing the informed consent form); * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; * Expected survival greater than 12 weeks; * At least one measurable lesion according to RECIST v1.1 criteria; * Laboratory test results meeting the following criteria (no blood transfusion within 14 days or hematopoietic growth factor administration within 7 days prior to screening): 1. Hemoglobin (HGB) ≥ 90 g/L; 2. Absolute neutrophil count (NEUT) ≥ 1.5×10⁹/L; 3. Platelet count (PLT) ≥ 90×10⁹/L; 4. Total bilirubin (TBIL) ≤ 1.5×Upper Limit of Normal (ULN); 5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (≤ 5×ULN if liver metastases are present); 6. Serum creatinine (CR) ≤ 1.3×ULN or creatinine clearance rate (CCR) ≥ 50 mL/min; 7. Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy within the past 2 weeks); * Lung cancer confirmed by histology or cytology； * Willing to provide qualified tumor tissue samples for immunohistochemical and amplification testing, unless the participant has no eligible archived specimens and is unsuitable or refuses re-biopsy; * Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion, with a negative serum or urine pregnancy test within 7 days before enrollment; male participants must agree to use effective contraception during the study and for 6 months after study completion (see Section 5.5 for details).
Exclusion criteria
* History of or concurrent other malignancies, except for: other malignancies treated with surgery alone and achieving ≥5 years of disease-free survival (DFS); or cured carcinoma in situ of cervix, non-melanoma skin cancer, or superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading basement membrane)\]. * Diseases affecting intravenous injection or blood sampling. * Adverse reactions from prior therapies not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grade ≤1, except for: grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant asymptomatic grade 2 laboratory abnormalities, hypothyroidism stabilized with hormone replacement, or other toxicities judged by investigator as non-safety risks. * Major surgery (Grade 3 or above per National Surgical Classification Catalog 2022), significant traumatic injury within 4 weeks prior to first dose, planned major surgery during study (except protocol-specified procedures), or presence of unhealed wounds/fractures. * Any bleeding or hemorrhagic events ≥CTCAE grade 3 within 4 weeks prior to first dose. * Arterial/venous thromboembolic events within 6 months prior to first dose, including: cerebrovascular accidents (including transient ischemic attack (TIA), excluding lacunar infarction), deep vein thrombosis, or pulmonary embolism (implantable venous port- or catheter-related thrombosis or superficial venous thrombosis not considered "severe" thromboembolism). * Active viral hepatitis with poor control, except: hepatitis B surface antigen (HBsAg)-positive participants with HepatitisBvirus Deoxyribonucleic acid (HBV DNA) \<500 IU/mL (2500 copies/mL) who agree to receive anti-HBV therapy throughout study; or hepatitis C virus (HCV)-infected participants (Hepatitis C Virus Antibody or Ribonucleic Acid positive) with hepatitis C virus Ribonucleic Acid (HCV RNA) ≤ULN continuing approved antiviral therapy. * Active syphilis requiring treatment. * Active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced/radiation pneumonitis requiring treatment, clinically significant active pneumonia, history of interstitial lung disease (ILD) requiring treatment, or current ILD. * History of psychotropic drug abuse or mental disorders. * Prior or planned allogeneic bone marrow or solid organ transplantation. * History of hepatic encephalopathy. * Significant cardiovascular diseases including: 1. Cardiac dysfunction ≥New York Heart Association (NYHA) class II or Left Ventricular Ejection Fractions (LVEF) \<50% by echocardiography; 2. Clinically significant ventricular arrhythmia history (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or arrhythmias requiring continuous antiarrhythmic therapy (participants with stable atrial fibrillation controlled solely by β-blockers may be included after investigator assessment); 3. Unstable angina; 4. Myocardial infarction within 12 months; 5. Cardio contraction time (QTc) \>450ms (male) or \>470ms (female) (if abnormal, measure three times at ≥2-minute intervals and average; corrected by Fridericia or Bazett method); 6. Congenital long QT syndrome or family history. * Active or uncontrolled severe infection (≥CTCAE grade 2). * Renal failure requiring hemodialysis or peritoneal dialysis. * Immunodeficiency including HIV positivity or other acquired/congenital immunodeficiency diseases. * Uncontrolled autoimmune diseases requiring immunosuppressants or systemic corticosteroids (\>10mg prednisone/day equivalent) within 7 days prior to first dose. * Epilepsy requiring treatment. * Poorly controlled diabetes (fasting blood glucose \>10mmol/L). * Tumor-related conditions and treatments: 1. Chemotherapy, immunotherapy, or small-molecule targeted therapy within 3 weeks prior to first dose or within 5 half-lives (whichever shorter); prior local radiotherapy allowed if: completed \>4 weeks (\>2 weeks for brain) before study treatment, and target lesions are outside radiation field or show progression within field; 2. National Medical Products Administration (NMPA)-approved traditional Chinese medicines with antitumor indications within 1 week prior to first dose; 3. Tumor invading major vessels or judged likely to cause fatal hemorrhage; 4. Uncontrolled effusions/ascites requiring recurrent drainage; 5. Spinal cord compression, leptomeningeal metastases, or brain metastases with symptoms controlled \<4 weeks, or requiring steroids/dehydrating agents within 2 weeks before treatment. * Known hypersensitivity to study drug or excipients. * Prior treatment with: Epidermal Growth Factor Receptor/cellular-mesenchymal epithelial transition factor (EGFR/c-Met)-targeted antibody-drug conjugates (ADCs); or topoisomerase I inhibitors (Non-Small Cell Lung Cancer only) or topoisomerase I inhibitor-based ADCs. * Prior EGFR/c-Met-targeted Monoclonal Antibody (mAbs)/bispecifics with: ≥grade 4 toxicity, permanent discontinuation due to toxicity, ≥grade 3 infusion reactions, or ≥grade 3 myalgia. * Participation in other antitumor clinical trials within 4 weeks prior to first dose. * Other conditions judged by investigator to jeopardize participant safety or study completion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase II Dosage for the Treatment (RP2D) | Baseline up to 21 days | Recommended phase II dosage for the treatment of advanced Lung Cancer. |
| Objective Response Rate (ORR) | Baseline up to 6 mouths | Objective response rate for the treatment of advanced Lung Cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | Baseline up to 6 mouths | Disease control rate for the treatment of advanced Lung Cancer. |
| Duration of Relief (DOR) | Baseline up to 2 years | Duration of relief for the treatment of advanced Lung Cancer. |
| Progression-Free Survival | Baseline up to 2 years | Progression-free survival for the treatment of advanced Lung Cancer. |
| Overall Survival (OS) | Baseline up to 3 years | Overall survival for the treatment of advanced Lung Cancer. |
| Adverse Events (AE) | Baseline up to 2 years | Numbers of participant with incidence and severity of adverse events, serious adverse events, and adverse events associated with investigational drugs (including investigational drugs and control drugs), as well as abnormal laboratory indicators were evaluated. |
| Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (NAb) | Cycle 1 day 1, Cycle 4 day 1, Cycle 6 day 1, Cycle 12 daye 1: 60 minutes before administration (21 days as a treatment cycle) | Immunogenicity in patients with advanced lung cancer, Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (NAb). |
| Peak concentration (Cmax) | Before administration, 30 minuets, 15 minuets after administration | The plasma concentration at which the rate of administration and rate of elimination are in equilibrium. |
| Plasma concentration at steady state (Cav, SS) | Pre-dose of day 1 on multiple dose and 2, 6, 24, 72 hours, 7, 14 days post-dose on multiple dose of day 1 | The plasma concentration at which the rate of administration and rate of elimination are in equilibrium. |
Countries
China
Contacts
CONTACTShengxiang Ren, Doctor
CONTACTZhijie Wang, Doctor
Outcome results
None listed